Can urinary PCA3 supplement PSA in the early detection of prostate cancer?
Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Instit...
Uložené v:
| Vydané v: | Journal of clinical oncology Ročník 32; číslo 36; s. 4066 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
20.12.2014
|
| Predmet: | |
| ISSN: | 1527-7755, 1527-7755 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA.
In all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score > 60) and the negative predictive value (NPV) for a repeat biopsy (at a score < 20).
For the detection of any cancer, PPV was 80% (95% CI, 72% to 86%) in the initial biopsy group, and NPV was 88% (95% CI, 81% to 93%) in the repeat biopsy group. The addition of PCA3 to individual risk estimation models (which included age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cancer and of high-grade cancer.
These data independently support the role of PCA3 in reducing the burden of prostate biopsies among men undergoing a repeat prostate biopsy. For biopsy-naive patients, a high PCA3 score (> 60) significantly increases the probability that an initial prostate biopsy will identify cancer. |
|---|---|
| AbstractList | Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA.PURPOSEGiven the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA.In all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score > 60) and the negative predictive value (NPV) for a repeat biopsy (at a score < 20).PATIENTS AND METHODSIn all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score > 60) and the negative predictive value (NPV) for a repeat biopsy (at a score < 20).For the detection of any cancer, PPV was 80% (95% CI, 72% to 86%) in the initial biopsy group, and NPV was 88% (95% CI, 81% to 93%) in the repeat biopsy group. The addition of PCA3 to individual risk estimation models (which included age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cancer and of high-grade cancer.RESULTSFor the detection of any cancer, PPV was 80% (95% CI, 72% to 86%) in the initial biopsy group, and NPV was 88% (95% CI, 81% to 93%) in the repeat biopsy group. The addition of PCA3 to individual risk estimation models (which included age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cancer and of high-grade cancer.These data independently support the role of PCA3 in reducing the burden of prostate biopsies among men undergoing a repeat prostate biopsy. For biopsy-naive patients, a high PCA3 score (> 60) significantly increases the probability that an initial prostate biopsy will identify cancer.CONCLUSIONThese data independently support the role of PCA3 in reducing the burden of prostate biopsies among men undergoing a repeat prostate biopsy. For biopsy-naive patients, a high PCA3 score (> 60) significantly increases the probability that an initial prostate biopsy will identify cancer. Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the overdiagnosis of low-risk and the underdiagnosis of high-grade prostate cancer. To improve early-detection biopsy decisions, the National Cancer Institute conducted a prospective validation trial to assess the diagnostic performance of the prostate cancer antigen 3 (PCA3) urinary assay for the detection of prostate cancer among men screened with PSA. In all, 859 men (mean age, 62 years) from 11 centers scheduled for a diagnostic prostate biopsy between December 2009 and June 2011 were enrolled. The primary outcomes were to assess whether PCA3 could improve the positive predictive value (PPV) for an initial biopsy (at a score > 60) and the negative predictive value (NPV) for a repeat biopsy (at a score < 20). For the detection of any cancer, PPV was 80% (95% CI, 72% to 86%) in the initial biopsy group, and NPV was 88% (95% CI, 81% to 93%) in the repeat biopsy group. The addition of PCA3 to individual risk estimation models (which included age, race/ethnicity, prior biopsy, PSA, and digital rectal examination) improved the stratification of cancer and of high-grade cancer. These data independently support the role of PCA3 in reducing the burden of prostate biopsies among men undergoing a repeat prostate biopsy. For biopsy-naive patients, a high PCA3 score (> 60) significantly increases the probability that an initial prostate biopsy will identify cancer. |
| Author | Busby, J Erik Srivastava, Sudhir Joon, Aron Y Lotan, Yair Partin, Alan W Viterbo, Rosalia Kagan, Jacob Sokoll, Lori Bidair, Mohamed Feng, Ziding Sanda, Martin G Lin, Daniel W Kibel, Adam S Dahlgren, Jackie Thompson, Ian Taneja, Samir S Wei, John T Chan, Daniel W Brown, Elissa |
| Author_xml | – sequence: 1 givenname: John T surname: Wei fullname: Wei, John T email: jtwei@umich.edu organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA. jtwei@umich.edu – sequence: 2 givenname: Ziding surname: Feng fullname: Feng, Ziding organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 3 givenname: Alan W surname: Partin fullname: Partin, Alan W organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 4 givenname: Elissa surname: Brown fullname: Brown, Elissa organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 5 givenname: Ian surname: Thompson fullname: Thompson, Ian organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 6 givenname: Lori surname: Sokoll fullname: Sokoll, Lori organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 7 givenname: Daniel W surname: Chan fullname: Chan, Daniel W organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 8 givenname: Yair surname: Lotan fullname: Lotan, Yair organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 9 givenname: Adam S surname: Kibel fullname: Kibel, Adam S organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 10 givenname: J Erik surname: Busby fullname: Busby, J Erik organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 11 givenname: Mohamed surname: Bidair fullname: Bidair, Mohamed organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 12 givenname: Daniel W surname: Lin fullname: Lin, Daniel W organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 13 givenname: Samir S surname: Taneja fullname: Taneja, Samir S organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 14 givenname: Rosalia surname: Viterbo fullname: Viterbo, Rosalia organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 15 givenname: Aron Y surname: Joon fullname: Joon, Aron Y organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 16 givenname: Jackie surname: Dahlgren fullname: Dahlgren, Jackie organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 17 givenname: Jacob surname: Kagan fullname: Kagan, Jacob organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 18 givenname: Sudhir surname: Srivastava fullname: Srivastava, Sudhir organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA – sequence: 19 givenname: Martin G surname: Sanda fullname: Sanda, Martin G organization: John T. Wei, University of Michigan, Ann Arbor, MI; Ziding Feng, Elissa Brown, Aron Y. Joon, Jackie Dahlgren, Fred Hutchinson Cancer Research Center; Daniel W. Lin, University of Washington, Seattle, WA; Alan W. Partin, Lori Sokoll, Daniel W. Chan, Johns Hopkins University, Baltimore; Jacob Kagan, Sudhir Srivastava, National Cancer Institute, Bethesda, MD; Ian Thompson, The University of Texas San Antonio, San Antonio; Yair Lotan, The University of Texas Southwestern Medical Center, Dallas, TX; Adam S. Kibel, Harvard University, Cambridge; Martin G. Sanda, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA; J. Erik Busby, University of South Carolina, Greenville, SC; Mohamed Bidair, San Diego Clinical Trials, San Diego, CA; Samir S. Taneja, New York University, New York, NY; and Rosalia Viterbo, Fox Chase Cancer Center, Philadelphia, PA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25385735$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNjztrwzAYRUVJaR7t3qlo7GJXT0ueSjDpIwQSaHYjy5-oiy27ljzk3zfQFDrdOxzu5SzRzPceELqnJKWMkKdtsU8ZoTyVLNWSyCu0oJKpRCkpZ__6HC1D-CKECs3lDZozybVUXC7QtjAeT2PjzXjCh2LNcZiGoYUOfMSHjzVuPI6fgMGM7QnXEMHGpve4d3gY-xBNBGyNtzA-36JrZ9oAd5dcoePL5li8Jbv963ux3iVWZCwmrJJUCVY7wSpNuM5B8NwqXWviiOOaGq415JkwzDrrWF4RsBRMJhUjkrIVevydPf9_TxBi2TXBQtsaD_0USprxXOScU35GHy7oVHVQl8PYdGfP8k-f_QAqEFxo |
| CitedBy_id | crossref_primary_10_1007_s10719_022_10043_1 crossref_primary_10_1016_j_ucl_2015_08_002 crossref_primary_10_1016_j_ucl_2015_08_003 crossref_primary_10_1515_cclm_2019_0693 crossref_primary_10_1002_sim_7008 crossref_primary_10_1016_j_sbsr_2025_100826 crossref_primary_10_3389_fonc_2021_740868 crossref_primary_10_1007_s40291_017_0271_2 crossref_primary_10_1007_s10549_021_06496_x crossref_primary_10_1007_s00092_015_0715_0 crossref_primary_10_3390_ncrna5010010 crossref_primary_10_1177_17562872221103988 crossref_primary_10_1186_s12894_016_0159_1 crossref_primary_10_1016_j_soncn_2017_02_003 crossref_primary_10_1373_jalm_2017_025809 crossref_primary_10_3390_ijms23020628 crossref_primary_10_3390_cancers16020316 crossref_primary_10_1016_j_cca_2024_117824 crossref_primary_10_1016_j_semradonc_2016_09_001 crossref_primary_10_1186_s12929_020_00654_x crossref_primary_10_1002_jcla_24810 crossref_primary_10_1200_JCO_2017_76_4050 crossref_primary_10_3389_fonc_2025_1534612 crossref_primary_10_1002_sim_6790 crossref_primary_10_1111_iju_14464 crossref_primary_10_1097_MD_0000000000023372 crossref_primary_10_25259_Cytojournal_36_2024 crossref_primary_10_1016_j_euf_2015_07_007 crossref_primary_10_2147_RRU_S401131 crossref_primary_10_3390_ijerph14030270 crossref_primary_10_1016_j_patol_2018_04_003 crossref_primary_10_1016_j_eururo_2017_10_036 crossref_primary_10_1097_JU_0000000000003492 crossref_primary_10_1200_JCO_2014_58_5547 crossref_primary_10_1002_sim_7894 crossref_primary_10_1016_j_cca_2015_06_009 crossref_primary_10_1016_j_critrevonc_2025_104699 crossref_primary_10_1016_j_eururo_2015_04_039 crossref_primary_10_1259_bjr_20200484 crossref_primary_10_2174_0929867329666220607162250 crossref_primary_10_1002_ijc_34388 crossref_primary_10_1177_15330338241290029 crossref_primary_10_1016_j_anndiagpath_2021_151801 crossref_primary_10_2174_0929867325666180914115416 crossref_primary_10_3389_fgene_2019_00281 crossref_primary_10_3390_ijms22189926 crossref_primary_10_1016_j_molonc_2015_12_010 crossref_primary_10_3390_jpm11070664 crossref_primary_10_1016_j_phrs_2024_107539 crossref_primary_10_1007_s11934_018_0828_6 crossref_primary_10_1002_cam4_4629 crossref_primary_10_1631_jzus_B1600441 crossref_primary_10_5858_arpa_2017_0185_OA crossref_primary_10_1038_s41391_019_0149_y crossref_primary_10_1038_s41419_019_1804_x crossref_primary_10_1038_s41391_018_0124_z crossref_primary_10_1038_s41420_023_01625_5 crossref_primary_10_1016_j_ccell_2016_03_010 crossref_primary_10_3389_fonc_2019_01225 crossref_primary_10_1016_j_lungcan_2015_11_002 crossref_primary_10_1016_j_euf_2015_08_001 crossref_primary_10_1177_18758592241308755 crossref_primary_10_1002_cncr_31141 crossref_primary_10_3390_cancers16010165 crossref_primary_10_1016_j_isci_2025_111896 crossref_primary_10_1016_j_rcl_2017_10_002 crossref_primary_10_1016_j_critrevonc_2017_08_002 crossref_primary_10_1186_s12943_017_0756_y crossref_primary_10_1016_j_snb_2020_128812 crossref_primary_10_1053_j_seminoncol_2017_02_001 crossref_primary_10_1016_j_urology_2020_07_042 crossref_primary_10_1038_pcan_2015_48 crossref_primary_10_3390_diagnostics8040068 crossref_primary_10_1007_s10555_017_9718_5 crossref_primary_10_3390_ijms24032185 crossref_primary_10_3390_biomedicines9080921 crossref_primary_10_3390_cancers14215316 crossref_primary_10_1007_s00261_020_02496_5 crossref_primary_10_1177_2051415816656121 crossref_primary_10_1111_biom_12480 crossref_primary_10_1097_MOU_0000000000000382 crossref_primary_10_1097_MOU_0000000000000384 crossref_primary_10_1007_s12561_022_09343_9 crossref_primary_10_1016_j_acuro_2020_03_005 crossref_primary_10_36290_xon_2019_015 crossref_primary_10_1080_14737159_2023_2277366 crossref_primary_10_1177_1756287221997186 crossref_primary_10_1016_j_ucl_2017_07_001 crossref_primary_10_1016_j_urology_2017_05_028 crossref_primary_10_1038_s41391_020_00297_x crossref_primary_10_3390_ijms22094367 crossref_primary_10_1016_j_juro_2017_01_058 crossref_primary_10_1097_MOU_0000000000000315 crossref_primary_10_3390_cancers13122949 crossref_primary_10_1016_j_mce_2018_10_023 crossref_primary_10_1097_MOU_0000000000000316 crossref_primary_10_1186_s12894_015_0111_9 crossref_primary_10_1007_s00120_017_0418_0 crossref_primary_10_1038_s41585_019_0178_2 crossref_primary_10_3390_diagnostics8030062 crossref_primary_10_1186_s12957_024_03643_8 crossref_primary_10_1016_j_euros_2022_10_017 crossref_primary_10_1158_1078_0432_CCR_16_1245 crossref_primary_10_5534_wjmh_230386 crossref_primary_10_1016_j_prnil_2016_04_002 crossref_primary_10_1177_1010428318799255 crossref_primary_10_1038_nrurol_2015_159 crossref_primary_10_1073_pnas_1507882112 crossref_primary_10_1038_s41419_020_2674_y crossref_primary_10_1016_j_isci_2021_103622 crossref_primary_10_3390_ijms20081813 crossref_primary_10_1007_s11298_015_5453_9 crossref_primary_10_5604_01_3001_0015_0030 crossref_primary_10_1038_s41598_023_30865_9 crossref_primary_10_1016_j_ygeno_2021_06_029 crossref_primary_10_1080_14737140_2018_1502086 crossref_primary_10_1093_carcin_bgy167 crossref_primary_10_1111_rssc_12163 crossref_primary_10_1016_j_clgc_2020_03_005 crossref_primary_10_1016_j_urolonc_2021_09_007 crossref_primary_10_1038_s41391_020_00272_6 crossref_primary_10_1016_j_euf_2018_01_010 crossref_primary_10_1148_radiol_241030 crossref_primary_10_1007_s11934_015_0537_3 crossref_primary_10_1038_pcan_2017_16 crossref_primary_10_1038_s41391_019_0127_4 crossref_primary_10_1038_s41391_022_00633_3 crossref_primary_10_1016_j_canlet_2019_08_010 crossref_primary_10_1136_medethics_2019_105979 crossref_primary_10_3892_ol_2024_14770 crossref_primary_10_1177_00045632211041890 crossref_primary_10_3390_cancers13133373 crossref_primary_10_1186_s12885_015_1623_0 crossref_primary_10_1186_s12894_020_00712_4 crossref_primary_10_1073_pnas_1805337115 crossref_primary_10_1007_s15015_015_1863_5 crossref_primary_10_1016_j_acuroe_2020_07_004 crossref_primary_10_1016_j_eururo_2015_09_002 crossref_primary_10_1016_j_rcl_2016_10_011 crossref_primary_10_1111_bju_15968 crossref_primary_10_1186_s12955_018_0870_6 crossref_primary_10_3390_ijms20071637 crossref_primary_10_1016_j_critrevonc_2017_11_007 crossref_primary_10_1097_PAP_0000000000000245 crossref_primary_10_1200_JCO_2015_61_6532 crossref_primary_10_1016_j_eururo_2019_05_013 crossref_primary_10_1038_pcan_2017_32 crossref_primary_10_1016_j_juro_2015_01_126 crossref_primary_10_1016_j_mam_2015_05_003 crossref_primary_10_1080_14737140_2018_1535316 crossref_primary_10_1016_j_clinbiochem_2023_04_011 crossref_primary_10_1016_j_euo_2021_01_010 crossref_primary_10_1016_j_urolonc_2024_05_011 crossref_primary_10_1002_pros_24442 crossref_primary_10_1002_pros_23355 |
| ContentType | Journal Article |
| Copyright | 2014 by American Society of Clinical Oncology. |
| Copyright_xml | – notice: 2014 by American Society of Clinical Oncology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2013.52.8505 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 25385735 |
| Genre | Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: U01-CA-086402 – fundername: NCI NIH HHS grantid: U10 CA180867 – fundername: NCI NIH HHS grantid: U24 CA086368 – fundername: NCI NIH HHS grantid: U01-CA96368 – fundername: NCI NIH HHS grantid: U24-CA115102 – fundername: NCI NIH HHS grantid: U24 CA115102 – fundername: NCI NIH HHS grantid: U01 CA086402 – fundername: NCI NIH HHS grantid: U01-CA513913 – fundername: NCI NIH HHS grantid: UG1 CA233180 |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AARDX AAWTL AAYEP ABBLC ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YFH YQY 7X8 |
| ID | FETCH-LOGICAL-c462t-2b51742df42b80389e439c78d80f0f381a388e964a2cfcf29b0ec1ea65720512 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 214 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000346247500011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Sun Nov 09 04:50:03 EST 2025 Mon Jul 21 06:02:22 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 36 |
| Language | English |
| License | 2014 by American Society of Clinical Oncology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c462t-2b51742df42b80389e439c78d80f0f381a388e964a2cfcf29b0ec1ea65720512 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2013.52.8505?role=tab |
| PMID | 25385735 |
| PQID | 1639493313 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1639493313 pubmed_primary_25385735 |
| PublicationCentury | 2000 |
| PublicationDate | 2014-12-20 |
| PublicationDateYYYYMMDD | 2014-12-20 |
| PublicationDate_xml | – month: 12 year: 2014 text: 2014-12-20 day: 20 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2014 |
| References | 25420437 - Nat Rev Urol. 2015 Jan;12(1):1 25366689 - J Clin Oncol. 2014 Dec 20;32(36):4033-4 26088225 - J Urol. 2015 Jul;194(1):115 |
| References_xml | – reference: 26088225 - J Urol. 2015 Jul;194(1):115 – reference: 25420437 - Nat Rev Urol. 2015 Jan;12(1):1 – reference: 25366689 - J Clin Oncol. 2014 Dec 20;32(36):4033-4 |
| SSID | ssj0014835 |
| Score | 2.5739086 |
| Snippet | Given the limited sensitivity and specificity of prostate-specific antigen (PSA), its widespread use as a screening tool has raised concerns for the... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 4066 |
| SubjectTerms | Aged Antigens, Neoplasm - urine Biopsy Early Detection of Cancer Humans Male Middle Aged Prospective Studies Prostate - pathology Prostate-Specific Antigen - blood Prostatic Neoplasms - diagnosis Risk Assessment |
| Title | Can urinary PCA3 supplement PSA in the early detection of prostate cancer? |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/25385735 https://www.proquest.com/docview/1639493313 |
| Volume | 32 |
| WOSCitedRecordID | wos000346247500011&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3Na8IwFA_bHGOXfbgv90UGw5PVNE1sehKRyZDpCvPgraT5AC-ts27gf7-XWvE0GOzSS2gpyct7v7z38vsh9AwRgwkZao9ooz3GKfMgrgvPADqQIqXWmpJd_y2cTMRsFsVVwq2o2iq3PrF01DpXLkfeAdwQMTh9-0Fv8ek51ShXXa0kNPZRDQYi19IVznZVBCZKgU2n3AookvOqTAmG0RkN3l1fV9DmtC044b8DzDLQDE__-4tn6KSCmLi_sYlztGeyOjoaV0X0OmrGG7rqdQtPd7evihZu4nhHZL2-QKOBzLDLxsvlGseDfoALpwFaJhRx_NHH8wwDfsTGkSRjbVZlW1eGc4sX7jIJwFisnFUte5doOnyZDl69SnvBU6xLVx5NHYU11ZbRVDgSPgPIRYVCC2KJhTAvAyFM1GWSKqssjVJilG9kl4cU9jm9QgdZnpkbhDWxQgc0VVxZ-DSTkW8I821IU5N2ddRAT9vZTMC0Xb1CZib_KpLdfDbQ9WZJksWGgyOh4Kh5GPDbP7x9h45hqUt6RkruUc3CxjYP6FB9r-bF8rG0GXhO4vEPjkbJyw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Can+urinary+PCA3+supplement+PSA+in+the+early+detection+of+prostate+cancer%3F&rft.jtitle=Journal+of+clinical+oncology&rft.au=Wei%2C+John+T&rft.au=Feng%2C+Ziding&rft.au=Partin%2C+Alan+W&rft.au=Brown%2C+Elissa&rft.date=2014-12-20&rft.eissn=1527-7755&rft.volume=32&rft.issue=36&rft.spage=4066&rft_id=info:doi/10.1200%2FJCO.2013.52.8505&rft_id=info%3Apmid%2F25385735&rft_id=info%3Apmid%2F25385735&rft.externalDocID=25385735 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |